Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Sodium-Glucose Cotransporter 2 Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
EMPAGLIFLOZIN 37,059 1,624 4.4% 12,216 2,614 64.3 yrs 46.0%
CANAGLIFLOZIN 24,411 544 2.2% 9,503 979 57.8 yrs 49.1%
DAPAGLIFLOZIN PROPANEDIOL 16,873 3,694 21.9% 2,425 434 63.4 yrs 48.3%
SOTAGLIFLOZIN 472 26 5.5% 82 1 73.0 yrs 49.6%

Head-to-Head Comparisons

EMPAGLIFLOZIN vs CANAGLIFLOZIN EMPAGLIFLOZIN vs DAPAGLIFLOZIN PROPANEDIOL EMPAGLIFLOZIN vs SOTAGLIFLOZIN CANAGLIFLOZIN vs DAPAGLIFLOZIN PROPANEDIOL CANAGLIFLOZIN vs SOTAGLIFLOZIN DAPAGLIFLOZIN PROPANEDIOL vs SOTAGLIFLOZIN
← Back to Sodium-Glucose Cotransporter 2 Inhibitor [EPC] Class side effects →